Omeros Corporation (OMER) is a Healthcare · Biotechnology company listed on NASDAQ. Price $17.87 (-3.14%), Market cap $0.89B, P/E ratio 10.75, 52-week low–high $2.97 ~ $17.18.
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compul
Financial statements, price targets, institutional (13F) holdings and related news for Omeros Corporation are updated in real time on BlackAll Trade.
Omeros Corporation trades at $17.87 (-3.14%). Real-time quotes and charts are available on BlackAll Trade.
Omeros Corporation has a market cap of about $0.89B. Its P/E ratio is 10.75.
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases.